Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walmsley Takes On Oncology: Can GSK Become A Power Player?

Executive Summary

GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.

Advertisement

Related Content

Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Sun Rises For GSK's Trelegy And Shingrix While It Sets For Advair
GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
GSK Bags Barron As R&D Boss As Vallance Joins UK Government
GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'
Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs
GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone
$350m Adaptimmune deal shows GSK still does cancer R&D
GSK Swaps Cancer For Vaccines As It Sheds Legacy Products, Not R&D

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel